{"title":"韩国病态肥胖患者超肥胖的代谢和减肥手术的早期手术效果。","authors":"Jin-Jo Kim","doi":"10.17476/jmbs.2025.14.1.76","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To know about the feasibility and effectiveness of metabolic/bariatric surgery (MBS) in Korean super obese patients.</p><p><strong>Materials and methods: </strong>We reviewed the medical records of 18 super obese (body mass index [BMI] ≥50 kg/m<sup>2</sup>) patients among 131 morbidly obese patients who underwent MBS at Incheon St. Mary's Hospital, the Catholic University of Korea from May 2011 to July 2024 and investigated the early surgical outcomes of these patients.</p><p><strong>Results: </strong>Male/female ratio was 10 to 8, the mean age was 35.4±10.6 year, the mean body weight was 161.6±35.2 (range 112.9-241) kg, and the mean BMI was 58.3±8.2 (range 50.0-78.7) kg/m<sup>2</sup>. Sleeve gastrectomy (SG) was performed in 10 patients, SG plus procedure (SG+) in 5 patients, single anastomosis duodenoileal bypass with SG (SADI-S) in 2 patients and long biliopancreatic limb Roux-en-Y gastric bypass (LBPL RYGB) in 1 patient. The mean operation time was 170.3±64.5 minute and the mean postoperative hospital stay was 9±4.6 day. There was no postoperative morbidity and no mortality. The percentage of total weight loss at 1 year after surgery was 34.3±0.6% in SG, 23.1±3.2% in SG+, 45.8±4.5% in SADI-S and 47% in LBPL RYGB.</p><p><strong>Conclusion: </strong>MBS was feasible and effective in Korean super obese patients. However, SG+ was less effective than expected in these patients.</p>","PeriodicalId":73828,"journal":{"name":"Journal of metabolic and bariatric surgery","volume":"14 1","pages":"76-80"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12059310/pdf/","citationCount":"0","resultStr":"{\"title\":\"Early Surgical Outcomes of Metabolic and Bariatric Surgery for Super Obesity in Korean Morbidly Obese Patients.\",\"authors\":\"Jin-Jo Kim\",\"doi\":\"10.17476/jmbs.2025.14.1.76\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To know about the feasibility and effectiveness of metabolic/bariatric surgery (MBS) in Korean super obese patients.</p><p><strong>Materials and methods: </strong>We reviewed the medical records of 18 super obese (body mass index [BMI] ≥50 kg/m<sup>2</sup>) patients among 131 morbidly obese patients who underwent MBS at Incheon St. Mary's Hospital, the Catholic University of Korea from May 2011 to July 2024 and investigated the early surgical outcomes of these patients.</p><p><strong>Results: </strong>Male/female ratio was 10 to 8, the mean age was 35.4±10.6 year, the mean body weight was 161.6±35.2 (range 112.9-241) kg, and the mean BMI was 58.3±8.2 (range 50.0-78.7) kg/m<sup>2</sup>. Sleeve gastrectomy (SG) was performed in 10 patients, SG plus procedure (SG+) in 5 patients, single anastomosis duodenoileal bypass with SG (SADI-S) in 2 patients and long biliopancreatic limb Roux-en-Y gastric bypass (LBPL RYGB) in 1 patient. The mean operation time was 170.3±64.5 minute and the mean postoperative hospital stay was 9±4.6 day. There was no postoperative morbidity and no mortality. The percentage of total weight loss at 1 year after surgery was 34.3±0.6% in SG, 23.1±3.2% in SG+, 45.8±4.5% in SADI-S and 47% in LBPL RYGB.</p><p><strong>Conclusion: </strong>MBS was feasible and effective in Korean super obese patients. However, SG+ was less effective than expected in these patients.</p>\",\"PeriodicalId\":73828,\"journal\":{\"name\":\"Journal of metabolic and bariatric surgery\",\"volume\":\"14 1\",\"pages\":\"76-80\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12059310/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of metabolic and bariatric surgery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17476/jmbs.2025.14.1.76\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/23 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of metabolic and bariatric surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17476/jmbs.2025.14.1.76","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/23 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
Early Surgical Outcomes of Metabolic and Bariatric Surgery for Super Obesity in Korean Morbidly Obese Patients.
Purpose: To know about the feasibility and effectiveness of metabolic/bariatric surgery (MBS) in Korean super obese patients.
Materials and methods: We reviewed the medical records of 18 super obese (body mass index [BMI] ≥50 kg/m2) patients among 131 morbidly obese patients who underwent MBS at Incheon St. Mary's Hospital, the Catholic University of Korea from May 2011 to July 2024 and investigated the early surgical outcomes of these patients.
Results: Male/female ratio was 10 to 8, the mean age was 35.4±10.6 year, the mean body weight was 161.6±35.2 (range 112.9-241) kg, and the mean BMI was 58.3±8.2 (range 50.0-78.7) kg/m2. Sleeve gastrectomy (SG) was performed in 10 patients, SG plus procedure (SG+) in 5 patients, single anastomosis duodenoileal bypass with SG (SADI-S) in 2 patients and long biliopancreatic limb Roux-en-Y gastric bypass (LBPL RYGB) in 1 patient. The mean operation time was 170.3±64.5 minute and the mean postoperative hospital stay was 9±4.6 day. There was no postoperative morbidity and no mortality. The percentage of total weight loss at 1 year after surgery was 34.3±0.6% in SG, 23.1±3.2% in SG+, 45.8±4.5% in SADI-S and 47% in LBPL RYGB.
Conclusion: MBS was feasible and effective in Korean super obese patients. However, SG+ was less effective than expected in these patients.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
